undamentalytics Newsletter
Sign in

AC Immune SA revenue

AC Immune SA's revenue was $4.3m in fiscal 2025, down 86.1% on the year before. Since fiscal 2015 ($40.6m) it has grown at a compound -20.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue4124217111160416314
Growth on the year before—−42.0%−12.7%−65.7%+>999%−85.2%−100.0%—+299.8%+88.2%−86.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
AC Immune SA $4.3m -86.1% -43.2%
Curis Inc $4.3m -62.2% -25.0%
Camp4 Therapeutics Corp $4.2m 40.2% —
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Ocugen, Inc. $4.6m -3.7% 26.3%
Entrada Therapeutics, Inc. $4.7m -94.1% —

Compare with peers

Head to head: ACIU vs CRISACIU vs CAMPACIU vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AC Immune SA's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AC Immune SA.